Careers  |  Sign In  |  Register

Latest in Oncology

The Future of ALK Inhibitors as First-Line Therapies in NSCLC

Dr. Saxena on the Future of Next-Generation ALK Inhibitors in NSCLC

Ashish Saxena, MD, PhD, assistant attending at New York-Presbyterian Hospital and assistant professor of medicine at Weill Cornell Medical College, reviews first-line therapies in non-small cell lung cancer. Dr. Saxena explains that, while no comparative research is available for brigatinib and alectinib,...
Results from a cohort study suggest that vision loss, a common side effect after plaque radiotherapy for uveal melanoma, may be mitigated or avoided entirely thanks to prophylactic anti-vascular endothelial growth factor treatment. By employing intravitreal bevacizumab patients had better outcomes...

Novel Treatment Options for Older AML Patients

Novel Strategies and Agents Emerge in AML Paradigm

Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in acute myeloid leukemia (AML) standards of care. In the past, clinicians and researchers have focused their...